A detailed history of Federated Hermes, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 211,642 shares of VRTX stock, worth $106 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
211,642
Previous 211,915 0.13%
Holding current value
$106 Million
Previous $88.6 Million 11.99%
% of portfolio
0.24%
Previous 0.21%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$392.81 - $485.53 $107,237 - $132,549
-273 Reduced 0.13%
211,642 $99.2 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $2.67 Million - $2.92 Million
6,554 Added 3.19%
211,915 $88.6 Million
Q4 2023

Jan 31, 2024

BUY
$343.0 - $410.68 $4.3 Million - $5.15 Million
12,542 Added 6.5%
205,361 $83.6 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $12 Million - $12.8 Million
35,371 Added 22.47%
192,819 $67.1 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $3.84 Million - $4.3 Million
-12,211 Reduced 7.2%
157,448 $55.4 Million
Q1 2023

May 08, 2023

BUY
$283.23 - $323.1 $5.28 Million - $6.02 Million
18,637 Added 12.34%
169,659 $53.5 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $1.53 Million - $1.73 Million
-5,368 Reduced 3.43%
151,022 $43.6 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $5.48 Million - $6.11 Million
-20,001 Reduced 11.34%
156,390 $45.3 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $15 Million - $18.7 Million
-63,757 Reduced 26.55%
176,391 $49.7 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $5.96 Million - $7.03 Million
-26,936 Reduced 10.09%
240,148 $62.7 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $2.91 Million - $3.67 Million
16,440 Added 6.56%
267,084 $58.7 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $14.3 Million - $16 Million
78,580 Added 45.67%
250,644 $45.5 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $18.5 Million - $21.8 Million
-98,665 Reduced 36.44%
172,064 $34.7 Million
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $12.3 Million - $14.4 Million
-59,586 Reduced 18.04%
270,729 $58.2 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $6.41 Million - $8.54 Million
-30,941 Reduced 8.56%
330,315 $78.1 Million
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $838,276 - $993,864
-3,279 Reduced 0.9%
361,256 $98.3 Million
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $7.74 Million - $10.2 Million
-34,322 Reduced 8.61%
364,535 $106 Million
Q1 2020

May 13, 2020

SELL
$199.77 - $247.81 $1.97 Million - $2.45 Million
-9,873 Reduced 2.42%
398,857 $94.9 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $4.58 Million - $6.15 Million
27,454 Added 7.2%
408,730 $89.5 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $9.4 Million - $10.6 Million
56,546 Added 17.41%
381,276 $64.6 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $605,764 - $700,561
-3,680 Reduced 1.12%
324,730 $59.5 Million
Q1 2019

May 10, 2019

BUY
$163.73 - $194.7 $12.2 Million - $14.5 Million
74,720 Added 29.45%
328,410 $60.4 Million
Q4 2018

Feb 13, 2019

SELL
$151.91 - $192.21 $7.28 Million - $9.22 Million
-47,947 Reduced 15.9%
253,690 $42 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $15.8 Million - $18.2 Million
-94,217 Reduced 23.8%
301,637 $58.1 Million
Q2 2018

Aug 10, 2018

BUY
$145.72 - $169.96 $22.5 Million - $26.2 Million
154,169 Added 63.79%
395,854 $67.3 Million
Q1 2018

May 09, 2018

BUY
$151.6 - $177.13 $29.2 Million - $34.1 Million
192,425 Added 390.63%
241,685 $39.4 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $278,129 - $315,144
-2,026 Reduced 3.95%
49,260 $0
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $7.6 Million - $8.32 Million
51,286
51,286 $7.8 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.